trending Market Intelligence /marketintelligence/en/news-insights/trending/UD6f23KvcGgBk_FfdWZvFQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Innovate Biopharmaceuticals to sell stock, warrants to fund celiac disease trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Innovate Biopharmaceuticals to sell stock, warrants to fund celiac disease trial

Innovate Biopharmaceuticals Inc. is selling common shares and warrants to certain investors to fund a study of its celiac disease treatment.

The Raleigh, N.C.-based drugmaker is selling up to 4,291,845 common shares at $2.33 each and 4,291,845 12-month term warrants exercisable at $4 per share to SDS Capital Partners II LLC and certain other investors. Innovate is also selling up to 2,575,107 five-year term warrants, which will be exercisable six months after issuance.

The five-year warrants will be priced equal to 125% of the volume weighted average price of the company's common shares for the 20-day period prior to the closing of the private placement, or the closing price of Innovate's common stock immediately before the placement's closing date — whichever of the two is greater.

Innovate will also have the right to call the 12-month warrants for cash exercise if the volume weighted average price of the company's stock exceeds $5.25 for 10 consecutive days following their issue dates.

The company plans to use the proceeds to start a phase 3 trial for INN-202, its lead program for celiac disease — a disorder in which eating gluten elicits an immune response in a patient, causing damage to the small intestine.

Part of the proceeds will also be used for working capital and general corporate purposes.

Closing of the concurrent sale of common shares and warrants is expected on March 18.